Cancer Research · us
Getting Cancer Cells to Break Down the Androgen Receptor: Prostate Cancer Drug Trial Reveals Differences Between Mutation Subgroups
The oral drug bavdegalutamide showed antitumor activity in an early trial, with more pronounced responses in a small subgroup of patients with specific receptor mutations. But the marked differences between subgroups also show that protein degradation therapies need more precise identification of suitable patients.
When prostate cancer continues to grow despite androgen suppression, cancer cells may still rely on the androgen receptor to transmit growth signals. Addressing this switch as it becomes increasingly resistant to treatment is a challenge in advanced disease. A phase I/II clinical trial showed that bavdegalutamide, an oral drug that prompts cells to break down the receptor, can reduce tumor activity in some patients, with particularly pronounced responses in those with specific receptor mutations.
The study was published in the Journal of Clinical Oncology on October 9, 2026, and Yale School of Medicine reported the findings on October 22. The open-label trial enrolled 239 patients with metastatic castration-resistant prostate cancer at 20 sites in the United States, all of whom had received at least one androgen receptor pathway inhibitor. Phase I enrolled 95 patients and established 420 milligrams once daily as the recommended phase II dose; phase II enrolled an additional 144 patients to further assess safety and antitumor activity across molecular subgroups.
Bavdegalutamide, also known as ARV-110, is a proteolysis-targeting chimera (PROTAC). It brings the androgen receptor into proximity with an E3 ubiquitin ligase involved in protein disposal, prompting the receptor to be tagged and sent to the cell's breakdown machinery. By removing the receptor, this strategy aims to weaken the signals cancer cells depend on for growth.
The strongest signal in phase II came from the subgroup with AR T878 and/or H875 mutations: among 20 evaluable patients, 60% had a decline in prostate-specific antigen (PSA) of at least half, and median radiographic progression-free survival was 11.1 months. However, the proportion with a PSA decline of at least half was only 4.3% in the subgroup with wild-type receptors or other alterations, and 3.1% in the subgroup with the L702H mutation or expression of the AR-V7 splice variant. These differences suggest that the receptor's molecular characteristics may influence drug activity, but are not yet sufficient to establish clinical criteria for treatment selection.
The Yale report also noted shrinkage of soft-tissue lesions and improvements in pain in some patients, but did not provide specific percentages for either outcome. A PSA decline can offer a clue to treatment response, but cannot be directly equated with longer life. Likewise, the 11.1 months of radiographic progression-free survival describes the observed outcome in that subgroup and cannot be interpreted as how much additional time was gained compared with existing treatments.
Regarding safety, 17.4% of patients in phase II experienced grade 3 treatment-related adverse events, and no treatment-related events of grade 4 or higher were observed. Common reactions included nausea, fatigue, vomiting, decreased appetite, and diarrhea, and 11.1% of patients discontinued treatment because of treatment-related adverse events. This indicates that even with a different mechanism of action, efficacy and tolerability still need to be weighed carefully.
Funded by Arvinas Androgen Receptor, Inc., the study provides evidence from a human trial for the androgen receptor degradation strategy and highlights the importance of patient subgrouping. However, the trial had no randomized control group, and the mutation subgroup with the strongest responses was small, so it cannot yet demonstrate superiority over current treatments or an improvement in overall survival. The next key step is to confirm, in larger controlled studies, which patients can obtain sustained, clinically meaningful benefits.